Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group

被引：4

作者：

Waszczuk-Gajda, Anna ^{[1
]}

Drozd-Sokolowska, Joanna ^{[1
]}

Boguradzki, Piotr ^{[1
]}

Dybko, Jaroslaw ^{[2
]}

Wrobel, Tomasz ^{[2
]}

Basak, Grzegorz Wladyslaw ^{[1
]}

Madry, Krzysztof ^{[1
]}

Snarski, Emilian ^{[1
]}

Charlinski, Grzegorz ^{[1
,3
]}

Fraczak, Ewa ^{[2
]}

Matuszkiewicz-Rowinska, Joanna ^{[4
]}

Klinger, Marian ^{[5
]}

Augustyniak-Bartosik, Hanna ^{[5
]}

Krajewska, Magdalena ^{[5
]}

Zebrowski, Pawel ^{[4
]}

Krol, Maria ^{[1
]}

Urbanowska, Elzbieta ^{[1
]}

Jurczyszyn, Artur ^{[6
]}

Taszner, Michal ^{[7
]}

Jedrzejczak, Wieslaw Wiktor ^{[1
]}

Dwilewicz-Trojaczek, Jadwiga ^{[1
]}

机构：

[1] Warsaw Med Univ, Dept Hematol Oncol & Internal Med, Banacha 1a, PL-02097 Warsaw, Poland

[2] Wroclaw Med Univ, Dept & Clin Hematol Blood Neoplasms & Bone Marrow, Wroclaw, Poland

[3] Nicolaus Copernicus Specialist Municipal Hosp, Dept Haematol, Torun, Poland

[4] Med Univ Warsaw, Dept Nephrol & Internal Med, Warsaw, Poland

[5] Wroclaw Med Univ, Dept Nephrol & Transplantat Med, Wroclaw, Poland

[6] Jagiellonian Univ, Dept Haematol, Krakow, Poland

[7] Med Univ Gdansk, Dept Hematol & Bone Marrow Transplantat, Gdansk, Poland

来源：

JOURNAL OF CLINICAL APHERESIS | 2018年 / 33卷 / 03期

关键词：

autologous peripheral stem cell mobilization; dialysis dependence; multiple myeloma; RENAL-FAILURE; G-CSF; MARROW-TRANSPLANTATION; DOSE CYCLOPHOSPHAMIDE; RANDOMIZED-TRIAL; CHEMOTHERAPY; PLERIXAFOR; BLOOD; EFFICACY; RESCUE;

D O I：

10.1002/jca.21584

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IntroductionHigh-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) improves the outcome of patients with multiple myeloma (MM). It seems that auto-HSCT is also a feasible therapeutic option in MM dialysis-dependent (MMDD) patients. However, to perform transplantation, a sufficient number of stem cells must be collected. Materials and MethodsGiven that data on mobilization of auto-HSC efficacy and safety in dialysis-dependent patients are limited, we report data from all Polish Centers belonging to the Polish Myeloma Study Group. Twenty-eight dialysis-dependent MM-patients were enrolled into this retrospective analysis. The study population comprised patients diagnosed between 2004 and 2015 in whom an attempt to collect auto-HSC was made (68%: women, median age: 56). Patients received granulocyte-colony stimulating factor (G-CSF) alone or in combination with chemotherapy and autologous peripheral blood stem cells (auto-PBSCs) were collected by leukapheresis. Results and ConclusionsThe success rate in terms of obtaining sufficient number of CD34(+) cells/kg for an auto-HSCT (2 x 10(6) cells/kg body weight) during the first mobilization attempt was 92% (26/28 patients), and for 2 auto-HSCTs (4 x 10(6) cells/kg) - was 75% (21/28 patients). After the second mobilization attempt (undertaken in 8 patients), a sufficient number of CD34(+)/kg cells for an auto-HSCT was obtained for all patients and the number of CD34(+)/kg collected cells was sufficient for 2 auto-HSCT in 6 additional patients. Hematologic toxicity and infections were the most frequent complications. Higher doses of cytarabine (>1.6 g/m(2)) and cyclophosphamide (> 2 g/m(2)) should be avoided in MMDD patients due to toxicity. Further studies are needed to establish mobilization regimens, confirm their safety, and dosing in MMDD patients.

引用

页码：249 / 258

页数：10

共 21 条

[21] Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure [J].

St Bernard, R. ;

Chodirker, L. ;

Masih-Khan, E. ;

Jiang, H. ;

Franke, N. ;

Kukreti, V. ;

Tiedemann, R. ;

Trudel, S. ;

Reece, D. ;

Chen, C. I. .

BONE MARROW TRANSPLANTATION, 2015, 50 (01) :95-99

← 1 2 3 →